These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36929093)

  • 21. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
    JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
    BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.
    Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD
    Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
    Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
    Hsu CC; Paciorek AT; Cooperberg MR; Roach M; Hsu IC; Carroll PR
    BJU Int; 2015 Nov; 116(5):713-20. PubMed ID: 25600860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):112-8. PubMed ID: 22300563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy.
    Choo R; Hruby G; Hong J; Bahk E; Hong E; Danjoux C; Morton G; DeBoer G
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):269-76. PubMed ID: 12023129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.
    Yu EY; Gulati R; Telesca D; Jiang P; Tam S; Russell KJ; Nelson PS; Etzioni RD; Higano CS
    J Clin Oncol; 2010 Jun; 28(16):2668-73. PubMed ID: 20421544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salvage radiotherapy after radical prostatectomy: prediction of biochemical outcomes.
    Kwon O; Kim KB; Lee YI; Byun SS; Kim JS; Lee SE; Hong SK
    PLoS One; 2014; 9(7):e103574. PubMed ID: 25072938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.
    Bianco FJ; Scardino PT; Stephenson AJ; Diblasio CJ; Fearn PA; Eastham JA
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):448-53. PubMed ID: 15890586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
    Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
    Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.
    Katz MS; Zelefsky MJ; Venkatraman ES; Fuks Z; Hummer A; Leibel SA
    J Clin Oncol; 2003 Feb; 21(3):483-9. PubMed ID: 12560439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less.
    Parekh A; Chen MH; Graham P; Mahal BA; Hirsch AE; Nakabayashi M; Evan C; Kantoff PW; Martin NE; Nguyen PL
    Clin Genitourin Cancer; 2015 Feb; 13(1):e1-6. PubMed ID: 25103271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy.
    Briganti A; Karnes RJ; Joniau S; Boorjian SA; Cozzarini C; Gandaglia G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Sun M; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
    Eur Urol; 2014 Sep; 66(3):479-86. PubMed ID: 24345725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage radiation therapy following radical prostatectomy. A national Danish study.
    Ervandian M; Høyer M; Petersen SE; Sengeløv L; Hansen S; Holmberg M; Sveistrup J; Meidahl Petersen P; Borre M
    Acta Oncol; 2016 May; 55(5):598-603. PubMed ID: 26399602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
    Vidal AC; Howard LE; De Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Lechpammer S; Flanders SC; Freedland SJ
    Cancer; 2019 Feb; 125(3):434-441. PubMed ID: 30427535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study.
    Tumati V; Jackson WC; Abugharib AE; Raj G; Roehrborn C; Lotan Y; Courtney K; Bagrodia A; Gahan JC; Zumsteg ZS; Folkert MR; Laine AM; Hannan R; Spratt DE; Desai NB
    BJU Int; 2018 Mar; 121(3):365-372. PubMed ID: 28581200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.